Literature DB >> 16412138

Idiopathic thrombocytopenic purpura (ITP) in the elderly: clinical course in 178 patients.

L Bizzoni1, M G Mazzucconi, M Gentile, C Santoro, S Bernasconi, F Chiarotti, R Foà, F Mandelli.   

Abstract

Idiopathic thrombocytopenic purpura (ITP) is often diagnosed in the elderly (age >or=65 yr), where it generally presents as a chronic disease. The objective of the present study was to describe the natural history of ITP in the elderly and to evaluate the risk of bleeding and the possible occurrence of other pathologies. We retrospectively evaluated 178 ITP patients (82 men, 96 women; mean age: 72 yr) diagnosed between 1981 and 1998. Therapy was started at diagnosis or during follow-up, depending on the platelet count and/or bleeding events. Sixty-six out of one hundred and seventy-eight patients (37%) initiated therapy at diagnosis; whereas in 11 of the 112 untreated patients (9.8%) therapy was necessary during the follow-up. Low-dose of prednisone was the first-line treatment in all patients (mean daily dose of 0.43 mg/kg). Forty-nine (63.6%) of the seventy-seven treated patients showed a response, 14 of these (28.6%) suffered a relapse. Another pathology occurred in 19 of the 178 patients (10.7%). We conclude that low-dose prednisone is an appropriate initial treatment for elderly persons. We also stress that an adequate follow-up is advisable, given that isolated thrombocytopenia could in some cases be the first sign of another underlying pathology.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16412138     DOI: 10.1111/j.1600-0609.2005.00602.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  5 in total

1.  American Society of Hematology 2019 guidelines for immune thrombocytopenia.

Authors:  Cindy Neunert; Deirdra R Terrell; Donald M Arnold; George Buchanan; Douglas B Cines; Nichola Cooper; Adam Cuker; Jenny M Despotovic; James N George; Rachael F Grace; Thomas Kühne; David J Kuter; Wendy Lim; Keith R McCrae; Barbara Pruitt; Hayley Shimanek; Sara K Vesely
Journal:  Blood Adv       Date:  2019-12-10

2.  Contributions of T lymphocyte abnormalities to therapeutic outcomes in newly diagnosed patients with immune thrombocytopenia.

Authors:  Zhenhua Zhao; Lei Yang; Guohua Yang; Yun Zhuang; Xifeng Qian; Xin Zhou; Dajiang Xiao; Yunfeng Shen
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

3.  Late results after splenectomy in adult idiopathic thrombocytopenic purpura.

Authors:  Rosario Vecchio; Eva Intagliata; Francesco La Corte; Salvatore Marchese; Rossella R Cacciola; Emma Cacciola
Journal:  JSLS       Date:  2015 Jan-Mar       Impact factor: 2.172

4.  Presence of Essential Hypertension or Diabetes Mellitus Is a Predictor of Intracranial Bleeding in Elderly Patients: A Study of 108 Patients with Isolated Thrombocytopenia from a Single Reference Center.

Authors:  Rajan Kapoor; Hara Prasad Pati; Manoranjan Mahapatra; Anuradha Monga
Journal:  Turk J Haematol       Date:  2015-06       Impact factor: 1.831

Review 5.  Management of immune thrombocytopenia: 2022 update of Korean experts recommendations.

Authors:  Young Hoon Park; Dae-Young Kim; Seongkoo Kim; Young Bae Choi; Dong-Yeop Shin; Jin Seok Kim; Won Sik Lee; Yeung-Chul Mun; Jun Ho Jang; Jong Wook Lee; Hoon Kook; On Behalf Of Korean Aplastic Anemia Working Party
Journal:  Blood Res       Date:  2022-03-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.